Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medeon BiodesignROCO:6499 -5.69%68 PS Ratio is 14.20 as of Jul. 19, 2026, which is 29% below its 10-year median of 19.87. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.29 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 804 Medical Devices & Instruments companies, Medeon Biodesign ranks worse than 88.06% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medeon Biodesign's share price is NT$64.60.
Medeon Biodesign's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.55. Hence, Medeon Biodesign's PS Ratio for today is 14.20.
Good Sign:
Medeon Biodesign Inc stock PS Ratio (=14.22) is close to 1-year low of 14.2.
The historical rank and industry rank for Medeon Biodesign's PS Ratio or its related term are showing as below:
ROCO:6499'
s PS Ratio Range Over the Past 10 Years
Min: 5.21 Med: 19.87 Max: 249.3
Current: 14.2
During the past 13 years, Medeon Biodesign's highest PS Ratio was 249.30. The lowest was 5.21. And the median was 19.87.
ROCO:6499's PS Ratio is ranked worse than 88.06% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.855
vs ROCO:6499: 14.20
During the past 12 months, the average Revenue per Share Growth Rate of Medeon Biodesign was 42.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 33.40% per year.
During the past 13 years, Medeon Biodesign's highest 3-Year average Revenue per Share Growth Rate was 130.00% per year. The lowest was -55.30% per year. And the median was 12.30% per year.
Back to Basics: PS Ratio
Medeon Biodesign (ROCO:6499) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medeon Biodesign PS Ratio Related Terms
Medeon Biodesign PS Ratio Historical Data
* Premium members only.
The historical data trend for Medeon Biodesign's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Medeon Biodesign's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medeon Biodesign PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medeon Biodesign's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medeon Biodesign's Share Price of today is NT$64.60. Medeon Biodesign's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.55.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medeon Biodesign (ROCO:6499) has a PS Ratio of 14.20 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medeon Biodesign and its competitors. This is 29% below median its historical median of 19.87. Over the past decade, Medeon Biodesign's PS Ratio has ranged from 5.21 to 249.30. According to the industry distribution chart, Medeon Biodesign ranks #708 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 88.1%.
Is Medeon Biodesign's PS Ratio too high?
Medeon Biodesign's current PS Ratio of 14.20 is 29% below median its 10-year median of 19.87. Over the past 10 years, this metric has ranged from a low of 5.21 to a high of 249.30. The Medical Devices & Instruments industry median PS Ratio is 2.86. Medeon Biodesign's value of 14.20 is 397.4% above this industry median. Based on the distribution chart, Medeon Biodesign ranks #708 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Medeon Biodesign ranks #708 out of 804 companies for PS Ratio. This places Medeon Biodesign in the lower half of its industry. The industry median PS Ratio is 2.86. Medeon Biodesign's value of 14.20 is 397.4% above this benchmark. Historically, Medeon Biodesign's own PS Ratio has ranged from 5.21 to 249.30 over the past decade. While the company's 10-year median is 19.87 vs. the industry median of 2.86, Medeon Biodesign has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medeon Biodesign's current PS Ratio of 14.20 is 397.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medeon Biodesign and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current PS Ratio is 14.20, which is 29% below median its own 10-year median of 19.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.29, compared to a current price of NT$64.60 — trading 39.8% below its estimated fair value. The current PS Ratio is 14.20, which is 29% below median its 10-year median of 19.87 and 397.4% above the Medical Devices & Instruments industry median of 2.86. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current PS Ratio is 14.20 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?
Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued.
The current stock price of NT$64.60 is trading 39.8% below its estimated GF Value™ of NT$107.29.
GuruFocus considers Medeon Biodesign to be Significantly Undervalued.
Key valuation signals for ROCO:6499:
PS Ratio: 14.20 (29% below median its 10-year median of 19.87)
GF Value™: NT$107.29 vs. price of NT$64.60 (39.8% below fair value)
Industry Position: 397.4% above the Medical Devices & Instruments median (#708 of 804)
No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score
Get the complete analysis for ROCO:6499
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6499 has been successfully added to your 
